

# Cytosolic Phospholipase A2 is Required for Fexofenadine's Therapeutic Effects Against Inflammatory Bowel Disease in Mice

Xiangli Zhao<sup>1</sup>, Ronghan Liu<sup>1</sup>, Yuehong Chen<sup>1</sup>, Aubryanna Hettinghouse<sup>1</sup>,

Chuan-ju Liu<sup>1,2,\*</sup>

**Supplementary Table S1.** Scoring of clinical symptoms. Clinical symptoms include rectal bleeding, body weight loss, and stool consistency.

Score of Clinical indicators	symptoms
Rectal Bleeding	
0	negative
2	blood trace
4	gross blood
Body weight loss	
0	less than 1%
1	between 5% and 10%
2	between 10% and 15%
3	between 15% and 20%
4	over 20%
Stool consistency	
0	normal
2	loose stool
4	diarrhea

**Supplementary Table S2.** The comparison of the clinical symptoms among H1R KO mice, cPLA2 KO mice, and corresponding WT mice at experimental endpoint. DSS-induced colitis model was established in 8-week-old indicated mice with ad libitum access to with drinking water containing 3% DSS for 10 days, followed by normal drinking water for 3 days, and then sacrificed. Data are mean  $\pm$  SE; \*  $p < 0.05$ .

	WT	H1R KO	significance
Bleeding score	2.8	2.5	ns
Stool score	2.7	2.4	ns
Body weight score	0.78	0.81	ns
colon length	5.2 cm	4.8 cm	ns

  

	WT	cPLA2 KO	significance
Bleeding score	2	1.6	*
Stool score	1.7	1.9	ns
Body weight score	0.85	0.95	ns
colon length	4 cm	4 cm	ns

**The mean value of the clinical scores at endpoint day**